Skip to Content

Vorapaxar Pregnancy and Breastfeeding Warnings

Vorapaxar is also known as: Zontivity

Medically reviewed on August 21, 2017

Vorapaxar Pregnancy Warnings

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

US FDA pregnancy category: B

Comments: There are no adequate and well-controlled studies of the use of this drug in pregnant women.

No embryofetal toxicities, malformations or maternal toxicities were observed in rats exposed during gestation. An overall increase in the number of litters with any malformation was observed at the highest dose, where systemic exposures were 89-fold higher than the human exposure at the recommended human dose. There are no controlled data in human pregnancy.

FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Vorapaxar Breastfeeding Warnings

Use should be avoided.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

See references

References for pregnancy information

  1. "Product Information. Zontivity (vorapaxar)." Merck & Company Inc, Whitehouse Station, NJ.

References for breastfeeding information

  1. "Product Information. Zontivity (vorapaxar)." Merck & Company Inc, Whitehouse Station, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide